Our industry-leading RNA biology and drug discovery capabilities drive our unique approach to address targets considered “undruggable” by conventional methods: we modulate the biology of mRNAs, preventing the production of disease-driving proteins. This opens a new path to targeting the drivers of cancer and other diseases.
We are focused on mRNAs of undruggable proteins and RBPs linked to specific disease phenotypes. Our industry-leading drug discovery platform enables us to leverage proprietary RNA structure determination capabilities and state-of-the-art RNA tools and technologies to directly target and modulate RNA biology.